Danaher companies Integrated DNA Technologies (IDT) and Beckman Coulter Life Sciences are forming a strategic partnership to automate IDT’s wide range of customizable next generation sequencing (NGS) assay solutions on the newly launched Biomek i3 Benchtop Liquid Handler.
The collaboration marks a significant step forward in enabling labs to streamline oncology research workflows with enhanced precision, scalability, and reproducibility, as oncology labs rely on reproducible NGS workflows to identify variants and drive precision medicine.
Through this partnership, IDT and Beckman Coulter Life Sciences will work to automate Archer FUSIONPlex and VARIANTPlex targeted sequencing assays, and xGen Hybrid Capture workflows, from IDT, on the Biomek i3 instrument. By pairing IDT’s trusted NGS assay chemistry with the precision and flexibility of the Biomek automation platform, researchers will benefit from reduced hands-on time, improved reproducibility, and throughput options tailored to their specific needs. The Biomek i3 system offers a compact footprint and advanced capabilities including optional on-deck thermocycling and intuitive software for rapid protocol development—making it an ideal solution for labs processing lower-throughput sample volumes without compromising data quality.
This collaboration builds on IDT’s broader work with automation leaders to deliver platform-agnostic, automation-ready solutions to accelerate cancer research.
Visit IDT for more information
